Publication:
Clinical Utility of Objective Tests for Dry Eye Disease: Variability over Time and Implications for Clinical Trials and Disease Management

dc.authorscopusid7201481759
dc.authorscopusid8752910800
dc.authorscopusid14720110800
dc.authorscopusid6701749743
dc.authorscopusid52663186800
dc.authorscopusid24179397100
dc.authorscopusid26646709900
dc.contributor.authorSullivan, B.D.
dc.contributor.authorCrews, L.A.
dc.contributor.authorSönmez, B.
dc.contributor.authorde la Paz, M.F.
dc.contributor.authorCömert, E.
dc.contributor.authorCharoenrook, V.
dc.contributor.authorde Araújo, A.L.
dc.date.accessioned2020-06-21T14:17:54Z
dc.date.available2020-06-21T14:17:54Z
dc.date.issued2012
dc.departmentOndokuz Mayıs Üniversitesien_US
dc.department-temp[Sullivan] Benjamin David, TearLab Corporation, San Diego, CA, United States; [Crews] Leslie A., TearLab Corporation, San Diego, CA, United States; [Sönmez] Bariş, Department of Ophthalmology, Ondokuz Mayis Üniversitesi, Samsun, Turkey; [de la Paz] María Fidéliz, Barraquer Centro de Oftalmologia, Barcelona, Barcelona, Spain; [Cömert] Ebru, Department of Ophthalmology, Ondokuz Mayis Üniversitesi, Samsun, Turkey; [Charoenrook] Víctor, Barraquer Centro de Oftalmologia, Barcelona, Barcelona, Spain; [de Araújo] Aline Lütz, Barraquer Centro de Oftalmologia, Barcelona, Barcelona, Spain; [Pepose] Jay S., Pepose Vision Institute, Chesterfield, MO, United States, Department of Ophthalmology and Visual Science, Washington University School of Medicine in St. Louis, St. Louis, MO, United States; [Berg] Michael S., TearLab Corporation, San Diego, CA, United States; [Kosheleff] Valerie P., TearLab Corporation, San Diego, CA, United States; [Lemp] Michael A., Department of Ophthalmology, Georgetown University School of Medicine, Washington, D.C., United States, The George Washington University School of Medicine and Health Sciences, Washington, D.C., United Statesen_US
dc.description.abstractPurpose: To evaluate the efficacy of commonly used biomarkers in dry eye disease management in a longitudinal observational case series study followed by an interventional study in a subset of subjects treated with cyclosporine A (0.05%). Methods: Bilateral tear osmolarity, Schirmer, tear film breakup time (TBUT), staining, meibomian grading, and Ocular Surface Disease Index were measured for a period of 3 consecutive months in participants recruited from a clinic-based population at 2 study sites. Fifty-two subjects completed the study (n = 16 mild/moderate, n = 36 severe; age, 47.1 ± 16.1 years). After the 3-month observation period, severe dry eye patients were prescribed topical cyclosporine A and evaluated for an additional 3 months. Results: Tear osmolarity (8.7 ± 6.3%) exhibited significantly less variability over a 3-month period than corneal staining (12.2 ± 8.8%, P = 0.040), conjunctival staining (14.8 ± 8.9%, P = 0.002), and meibomian grading (14.3 ± 8.8%, P < 0.0001) across the entire patient population. Osmolarity also demonstrated less variation than TBUT (11.7 ± 9.0%, P = 0.059), Schirmer tests (10.7 ± 9.2%, P = 0.67), and Ocular Surface Disease Index (9.3 ± 7.8%, P = 0.94), although the differences were not significant. Variation in osmolarity was less for mild dry eye patients (5.9 ± 3.1%) than severe dry eye patients (10.0 ± 6.9%, P = 0.038). After treatment, average osmolarity and variability were lowered from 341 ± 18 mOsm/L to 307 ± 8 mOsm/L (P < 0.0001, n = 10). A downward trend in symptoms followed changes in osmolarity, declining from 44 ± 17 mOsm/L to 38 ± 18 mOsm/L (P = 0.35). None of the other signs demonstrated a change after treatment. Conclusions: Over a 3-month period, tear film osmolarity was found to have the lowest variability among commonly used signs of dry eye disease. Reductions in osmolarity preceded changes in symptoms during therapy. Copyright © 2012 by Lippincott Williams & Wilkins.en_US
dc.identifier.doi10.1097/ICO.0b013e318242fd60
dc.identifier.endpage1008en_US
dc.identifier.issn0277-3740
dc.identifier.issn1536-4798
dc.identifier.issue9en_US
dc.identifier.pmid22475641
dc.identifier.scopus2-s2.0-84865523624
dc.identifier.scopusqualityQ1
dc.identifier.startpage1000en_US
dc.identifier.urihttps://doi.org/10.1097/ICO.0b013e318242fd60
dc.identifier.urihttps://hdl.handle.net/20.500.12712/16349
dc.identifier.volume31en_US
dc.identifier.wosWOS:000307827600007
dc.identifier.wosqualityQ2
dc.language.isoenen_US
dc.publisherLippincott Williams & Wilkinsen_US
dc.relation.ispartofCorneaen_US
dc.relation.journalCorneaen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectCyclosporineen_US
dc.subjectDry Eye Diseaseen_US
dc.subjectRestasisen_US
dc.subjectTear Osmolarityen_US
dc.subjectTearLaben_US
dc.titleClinical Utility of Objective Tests for Dry Eye Disease: Variability over Time and Implications for Clinical Trials and Disease Managementen_US
dc.typeArticleen_US
dspace.entity.typePublication

Files